IRWD Q2 2020 Earnings — Ironwood Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

IRWDIronwood Pharmaceuticals, Inc.

$603M

Q2 2020 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$89M-12.5% YoY

Gross Profit

$89M99.3% margin

Operating Income

$33M36.6% margin

Net Income

$25M28.2% margin

EPS (Diluted)

$0.16

QoQ Revenue Growth

+11.9%

Cash Flow

Operating Cash Flow

$20M

Free Cash Flow

$20M

Stock-Based Comp.

$7M

Balance Sheet

Total Assets

$444M

Total Liabilities

$480M

Stockholders' Equity

-$37M

Cash & Equivalents

$255M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$89M	$102M	-12.5%
Gross Profit	$89M	$91M	-2.3%
Operating Income	$33M	$22M	+51.6%
Net Income	$25M	$12M	+105.2%

Revenue Segments

Collaborative Arrangement Promotion Agreement

$1M34%

Collaborative Arrangement Co Promotion Agreement

$1M33%

License And Service

$900,00028%

Royalty

$200,0006%

Geographic Segments

J

$500,00021%

Europe And Other

$440,00019%

North America

$423,00018%

Canada And Mexico

$400,00017%

Europe

$400,00017%

China Hong Kong And Macau

$200,0008%